Profile data is unavailable for this security.
About the company
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
- Revenue in USD (TTM)1.21bn
- Net income in USD-16.59m
- Incorporated2015
- Employees2.90k
- LocationLivaNova PLC20 Eastbourne TerraceLONDON W2 6LGUnited KingdomGBR
- Phone+44 203 325 0662
- Websitehttps://www.livanova.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Premier Inc | 1.35bn | 119.54m | 1.99bn | 2.90k | 19.17 | 1.06 | 8.45 | 1.48 | 1.04 | 1.04 | 11.78 | 18.68 | 0.3976 | 5.85 | 3.07 | 464,262.40 | 3.15 | 7.08 | 4.10 | 8.95 | 65.96 | 61.29 | 7.93 | 16.05 | 0.8951 | -- | 0.2775 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| LeMaitre Vascular Inc | 205.62m | 37.68m | 2.02bn | 614.00 | 53.90 | 6.33 | 42.75 | 9.83 | 1.67 | 1.67 | 9.11 | 14.22 | 0.5964 | 1.13 | 7.19 | 334,887.60 | 10.93 | 9.02 | 11.81 | 9.93 | 67.70 | 65.83 | 18.32 | 15.45 | 5.86 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| Omnicell Inc | 1.08bn | -20.76m | 2.05bn | 3.65k | -- | 1.71 | 31.75 | 1.90 | -0.4558 | -0.4558 | 23.63 | 26.15 | 0.4818 | 5.64 | 4.20 | 296,013.40 | -0.9258 | 1.73 | -1.12 | 2.25 | 41.63 | 46.69 | -1.92 | 2.92 | 2.22 | -- | 0.322 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| Rxsight Inc | 115.18m | -36.77m | 2.10bn | 374.00 | -- | 7.63 | -- | 18.25 | -1.01 | -1.01 | 3.14 | 6.95 | 0.46 | 2.08 | 5.90 | 307,962.60 | -14.69 | -- | -15.83 | -- | 66.26 | -- | -31.93 | -- | 13.34 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| Irhythm Technologies Inc | 537.09m | -131.59m | 2.19bn | 2.00k | -- | 22.03 | -- | 4.07 | -4.26 | -4.26 | 17.40 | 3.18 | 0.7965 | 11.79 | 7.86 | 268,545.50 | -19.51 | -21.92 | -22.66 | -26.77 | 67.19 | 69.39 | -24.50 | -25.75 | 6.76 | -13.78 | 0.8667 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
| Conmed Corp | 1.28bn | 98.59m | 2.32bn | 4.00k | 23.86 | 2.63 | 13.60 | 1.82 | 3.15 | 3.15 | 40.81 | 28.61 | 0.5538 | 1.75 | 5.45 | 318,998.30 | 4.28 | 0.8972 | 4.94 | 1.02 | 55.32 | 54.95 | 7.73 | 1.65 | 1.13 | 4.20 | 0.5228 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Enovis Corp | 1.91bn | -107.11m | 2.44bn | 6.55k | -- | 0.7291 | 16.87 | 1.27 | -1.96 | -1.65 | 35.01 | 59.90 | 0.3872 | 1.53 | 5.52 | 292,209.20 | -2.16 | -0.3569 | -2.37 | -0.41 | 57.30 | 48.19 | -5.57 | -1.06 | 1.08 | 0.836 | 0.2902 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| Myriad Genetics, Inc. | 802.20m | -155.20m | 2.51bn | 2.70k | -- | 3.39 | -- | 3.13 | -1.80 | -1.80 | 9.20 | 8.15 | 0.7061 | 10.21 | 6.99 | 297,111.10 | -13.66 | -- | -16.32 | -- | 69.06 | -- | -19.35 | -- | 1.78 | -113.89 | 0.0498 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Inari Medical Inc | 547.47m | -57.05m | 2.55bn | 1.30k | -- | 5.99 | -- | 4.65 | -0.9838 | -0.9838 | 9.43 | 7.29 | 0.9141 | 1.59 | 7.56 | 421,133.80 | -9.53 | -0.5941 | -11.39 | -0.6696 | 87.15 | 89.06 | -10.42 | -0.6295 | 1.45 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| 10X Genomics Inc | 631.73m | -239.78m | 2.73bn | 1.26k | -- | 3.77 | -- | 4.33 | -2.02 | -2.02 | 5.31 | 6.01 | 0.6583 | 2.59 | 7.06 | 501,773.60 | -24.99 | -25.52 | -28.04 | -29.05 | 64.70 | 75.88 | -37.96 | -48.53 | 4.42 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| UFP Technologies Inc | 417.47m | 49.55m | 2.75bn | 3.09k | 55.91 | 8.87 | 44.81 | 6.59 | 6.41 | 6.41 | 54.02 | 40.42 | 1.02 | 4.26 | 6.68 | 134,971.50 | 12.08 | 9.69 | 13.85 | 10.95 | 28.02 | 26.33 | 11.87 | 10.14 | 1.63 | 21.63 | 0.1024 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| LivaNova PLC | 1.21bn | -16.59m | 2.76bn | 2.90k | -- | 2.22 | 91.88 | 2.28 | -0.3133 | -0.3133 | 22.29 | 22.88 | 0.5046 | 2.52 | 6.26 | 417,149.00 | -0.6876 | -6.01 | -0.7843 | -7.42 | 67.64 | 66.99 | -1.36 | -13.56 | 2.94 | 2.19 | 0.3347 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Tandem Diabetes Care Inc | 796.00m | -136.49m | 2.92bn | 2.40k | -- | 12.49 | -- | 3.67 | -2.09 | -2.09 | 12.21 | 3.57 | 0.8449 | 2.62 | 8.09 | 331,667.50 | -14.49 | -10.08 | -18.58 | -12.23 | 49.06 | 51.77 | -17.15 | -11.59 | 2.38 | -- | 0.598 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Quidelortho Corp | 2.83bn | -1.86bn | 3.05bn | 7.10k | -- | 0.9599 | -- | 1.08 | -27.79 | -27.79 | 42.35 | 47.30 | 0.372 | 2.58 | 9.15 | 399,239.40 | -24.40 | 11.34 | -27.51 | 12.91 | 47.89 | 62.71 | -65.60 | 20.93 | 0.7929 | 0.7895 | 0.4469 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
| Envista Holdings Corp | 2.53bn | -1.32bn | 3.27bn | 12.80k | -- | 1.10 | -- | 1.29 | -7.70 | -7.70 | 14.64 | 17.32 | 0.4207 | 4.08 | 6.37 | 197,937.50 | -21.98 | 1.94 | -26.29 | 2.34 | 54.89 | 57.65 | -52.25 | 5.29 | 1.90 | 3.92 | 0.3357 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
| Axonics Inc | 408.81m | -1.71m | 3.53bn | 797.00 | -- | 5.48 | 325.70 | 8.65 | -0.0291 | -0.0291 | 8.11 | 12.61 | 0.5856 | 1.12 | 7.81 | 512,934.80 | -0.2451 | -12.67 | -0.2618 | -13.76 | 75.89 | 70.04 | -0.4185 | -29.68 | 7.11 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
Data as of Sep 20 2024. Currency figures normalised to LivaNova PLC's reporting currency: US Dollar USD
49.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.40m | 11.81% |
| PRIMECAP Management Co.as of 30 Jun 2024 | 5.98m | 11.05% |
| Millennium Management LLCas of 09 Apr 2024 | 2.73m | 5.05% |
| Barrow, Hanley, Mewhinney & Strauss LLCas of 31 Mar 2024 | 2.36m | 4.36% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.00m | 3.69% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.74m | 3.21% |
| Columbia Management Investment Advisers LLCas of 31 Mar 2024 | 1.47m | 2.71% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.38m | 2.54% |
| Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 1.36m | 2.51% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.34m | 2.47% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
